Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance to Provide Genotyping for Sankyo in Potential Theranostics Deal

NEW YORK, Oct. 3 (GenomeWeb News) - Genaissance has licensed its HAP genotyping technology to Sankyo of Japan, the companies said today.

 

Under the agreement, the two firms aim to discover and validate genetic markers related to drug response and create a diagnostic test to guide therapy. Genaissance will receive license fees as well as payments for genotyping clinical samples. In addition, the company will have certain rights to co-develop and co-commercialize a companion genetic test.

 

Last month, Genaissance signed a deal with another Japanese pharma firm, Otsuka Pharmaceutical. "We hope to see more such agreements with Japanese companies in the future," said Genaissance CEO Kevin Rakin in a statement.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.